SK287351B6 - Farmaceutická kompozícia obsahujúca pioglitazón s glibenclamidom alebo s glimepiridom - Google Patents
Farmaceutická kompozícia obsahujúca pioglitazón s glibenclamidom alebo s glimepiridom Download PDFInfo
- Publication number
- SK287351B6 SK287351B6 SK794-96A SK79496A SK287351B6 SK 287351 B6 SK287351 B6 SK 287351B6 SK 79496 A SK79496 A SK 79496A SK 287351 B6 SK287351 B6 SK 287351B6
- Authority
- SK
- Slovakia
- Prior art keywords
- pharmaceutical composition
- pioglitazone
- glimepiride
- combination
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15350095 | 1995-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
SK79496A3 SK79496A3 (en) | 1997-01-08 |
SK287351B6 true SK287351B6 (sk) | 2010-08-09 |
Family
ID=15563926
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1449-2001A SK287287B6 (sk) | 1995-06-20 | 1996-06-18 | Farmaceutická kompozícia obsahujúca pioglitazón a metformín |
SK794-96A SK287351B6 (sk) | 1995-06-20 | 1996-06-18 | Farmaceutická kompozícia obsahujúca pioglitazón s glibenclamidom alebo s glimepiridom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1449-2001A SK287287B6 (sk) | 1995-06-20 | 1996-06-18 | Farmaceutická kompozícia obsahujúca pioglitazón a metformín |
Country Status (26)
Country | Link |
---|---|
US (44) | US5952356A (pt) |
EP (6) | EP2289556A3 (pt) |
JP (3) | JP3148973B2 (pt) |
KR (3) | KR970000233A (pt) |
CN (3) | CN1289082C (pt) |
AR (4) | AR005641A1 (pt) |
AT (2) | ATE438397T1 (pt) |
CA (3) | CA2179584C (pt) |
CY (4) | CY2424B1 (pt) |
CZ (2) | CZ291624B6 (pt) |
DE (4) | DE122009000064I1 (pt) |
DK (2) | DK0861666T3 (pt) |
ES (2) | ES2327383T5 (pt) |
FR (1) | FR09C0055I2 (pt) |
HK (2) | HK1010484A1 (pt) |
HU (1) | HUP9601698A3 (pt) |
LU (2) | LU91298I2 (pt) |
MX (1) | MX9602399A (pt) |
MY (1) | MY127530A (pt) |
NL (2) | NL300258I2 (pt) |
NO (5) | NO313226B1 (pt) |
PT (2) | PT861666E (pt) |
RU (5) | RU2323004C2 (pt) |
SK (2) | SK287287B6 (pt) |
TW (2) | TWI238064B (pt) |
ZA (1) | ZA965190B (pt) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CA2180296C (en) * | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
KR19990036290A (ko) | 1995-08-10 | 1999-05-25 | 로즈 암스트롱 | 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법 |
KR20050047560A (ko) * | 1996-04-05 | 2005-05-20 | 다께다 케미칼 인더스트리즈,리미티드 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는약제학적 조합물 |
NZ333723A (en) | 1996-07-15 | 2000-09-29 | Sankyo Co | A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
KR20070011651A (ko) * | 1997-06-18 | 2007-01-24 | 스미스클라인비이참피이엘시이 | 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료 |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
AU778947B2 (en) * | 1997-06-18 | 2004-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin |
US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
CN1114404C (zh) * | 1997-06-18 | 2003-07-16 | 史密丝克莱恩比彻姆有限公司 | 用噻唑烷二酮和二甲双胍治疗糖尿病 |
CA2294134A1 (en) * | 1997-06-18 | 1998-12-23 | Stephen Alistair Smith | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
AU783539B2 (en) * | 1997-06-18 | 2005-11-10 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and sulphonylurea |
GB9715306D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
AU782419B2 (en) * | 1997-07-18 | 2005-07-28 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
GB9715295D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
AU740299B2 (en) * | 1997-10-20 | 2001-11-01 | Dainippon Sumitomo Pharma Co., Ltd. | Fast-dissolving pharmaceutical composition |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US7105552B2 (en) | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
KR20010043455A (ko) * | 1998-06-30 | 2001-05-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 당뇨병 치료용 약학적 조성물 |
SI0974356T1 (en) * | 1998-07-15 | 2003-12-31 | Merck Sante | Tablets comprising a combination of metformin and glibenclamide |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
BR9915820A (pt) * | 1998-10-29 | 2001-10-30 | Univ Texas | Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação |
AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
AP1692A (en) * | 1998-11-12 | 2006-12-12 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
JP2002529504A (ja) * | 1998-11-12 | 2002-09-10 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物 |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US6958324B2 (en) * | 1998-12-02 | 2005-10-25 | Inotek Pharmaceuticals Corporation | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
DE69926400T2 (de) * | 1998-12-24 | 2006-05-24 | Metabasis Therapeutics Inc., San Diego | Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes |
US6756360B1 (en) | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
JP4799720B2 (ja) * | 1999-01-29 | 2011-10-26 | 武田薬品工業株式会社 | コーティング処理を施した打錠用杵 |
WO2000044554A1 (fr) * | 1999-01-29 | 2000-08-03 | Takeda Chemical Industries, Ltd. | Maillet de compression à revêtement traité |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
US6410802B1 (en) * | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
JP2000355550A (ja) * | 1999-04-14 | 2000-12-26 | Takeda Chem Ind Ltd | ケトーシス改善剤 |
KR100744359B1 (ko) * | 1999-04-23 | 2007-07-30 | 스미스클라인비이참피이엘시이 | 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도 |
GB9910693D0 (en) * | 1999-05-07 | 1999-07-07 | Univ Liverpool | A compound for use in medicine |
US6214842B1 (en) * | 1999-05-12 | 2001-04-10 | Michael S. Malamas | Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia |
ES2277842T3 (es) * | 1999-06-18 | 2007-08-01 | MERCK & CO., INC. | Derivados de ariltiazolidindiona y de ariloxazolidindiona. |
EP1849475A1 (en) | 1999-06-21 | 2007-10-31 | Eli Lilly & Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
AU779730B2 (en) * | 1999-06-30 | 2005-02-10 | Amgen, Inc. | Compounds for the modulation of PPARgamma activity |
DK1192137T3 (da) * | 1999-06-30 | 2013-11-11 | Amgen Inc | Forbindelser til modulering af PPAR-gamma aktivitet |
US6878749B2 (en) * | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
AU2005200818B2 (en) * | 1999-09-17 | 2008-07-17 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US7169407B1 (en) * | 1999-10-06 | 2007-01-30 | Toshio Miyata | Carbonyl stress-decreasing agent |
EP1218015A2 (en) * | 1999-10-08 | 2002-07-03 | Novartis AG | Pharmaceutical composition of nateglinide and another antidiabetic agent |
US6274622B1 (en) * | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
KR20070089259A (ko) | 1999-11-03 | 2007-08-30 | 브리스톨-마이어스스퀴브컴파니 | 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
MY125516A (en) * | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
US6402771B1 (en) | 1999-12-23 | 2002-06-11 | Guidant Endovascular Solutions | Snare |
US6660021B1 (en) | 1999-12-23 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Intravascular device and system |
US6575997B1 (en) | 1999-12-23 | 2003-06-10 | Endovascular Technologies, Inc. | Embolic basket |
GB9930688D0 (en) * | 1999-12-24 | 2000-02-16 | Smithkline Beecham Plc | Novel method of treatment |
EP1261373A2 (en) * | 1999-12-24 | 2002-12-04 | SmithKline Beecham plc | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
US6695813B1 (en) | 1999-12-30 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Embolic protection devices |
US7918820B2 (en) | 1999-12-30 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Device for, and method of, blocking emboli in vessels such as blood arteries |
US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
AU2001229601A1 (en) * | 2000-01-24 | 2001-07-31 | Inotek Corporation | Method and composition for modulating an immune response |
US6540982B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
EP1254667A4 (en) * | 2000-02-10 | 2003-03-12 | Takeda Chemical Industries Ltd | MEDICINE COMPRISING A COMBINATION |
AU2001234114A1 (en) * | 2000-02-24 | 2001-09-03 | Takeda Chemical Industries Ltd. | Drugs containing combined active ingredients |
US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6461639B2 (en) * | 2000-05-01 | 2002-10-08 | Aeropharm Technology, Inc. | Core formulation |
US6610272B1 (en) | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
US6296874B1 (en) * | 2000-05-01 | 2001-10-02 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and abiguanide |
US6451342B2 (en) | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US6270797B1 (en) * | 2000-05-18 | 2001-08-07 | Usv Limited | Sustained release pharmaceutical composition containing glipizide and method for producing same |
US6939362B2 (en) * | 2001-11-27 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Offset proximal cage for embolic filtering devices |
US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
US6964670B1 (en) | 2000-07-13 | 2005-11-15 | Advanced Cardiovascular Systems, Inc. | Embolic protection guide wire |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20040087597A1 (en) * | 2000-10-12 | 2004-05-06 | Masaki Kitahara | Preventives and remedies for complications of diabetes |
US6506203B1 (en) | 2000-12-19 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Low profile sheathless embolic protection system |
MXPA03006217A (es) | 2001-01-12 | 2004-10-15 | Sun Pharmaceutical Ind Ltd | Sistema de administracion espaciada de farmacos. |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
ES2240657T3 (es) | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
CA2439793A1 (en) * | 2001-03-02 | 2002-09-12 | Lichtwer Pharma Ag | Composition for the treatment of diabetes mellitus |
KR200249057Y1 (ko) * | 2001-03-22 | 2001-10-19 | 김진환 | 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치 |
DK1491540T3 (da) | 2001-03-30 | 2007-03-26 | Pfizer Prod Inc | Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer |
JPWO2002080924A1 (ja) * | 2001-04-03 | 2004-07-29 | 山之内製薬株式会社 | アリールエテンスルホンアミド誘導体の新規な用途 |
RU2324475C2 (ru) * | 2001-04-10 | 2008-05-20 | Сан Фармасьютикал Индастриз Лимитед | Состав, выделяемый в импульсном режиме в заданное время |
SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
JP2002360666A (ja) * | 2001-06-11 | 2002-12-17 | Takeda Chem Ind Ltd | コバルト合金を用いた打錠用杵臼 |
US6737401B2 (en) * | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US7338510B2 (en) | 2001-06-29 | 2008-03-04 | Advanced Cardiovascular Systems, Inc. | Variable thickness embolic filtering devices and method of manufacturing the same |
US6599307B1 (en) | 2001-06-29 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Filter device for embolic protection systems |
EP1429747A4 (en) * | 2001-07-10 | 2005-01-05 | Kos Life Sciences Inc | CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE |
CA2453784A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | A core formulation |
US6638294B1 (en) | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
DE10200138A1 (de) * | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
TWI327462B (en) * | 2002-01-18 | 2010-07-21 | Sumitomo Chemical Co | Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
AU2003235120A1 (en) * | 2002-04-26 | 2003-11-10 | Takeda Chemical Industries, Ltd. | Screening method |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
AU2003261298A1 (en) | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) * | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
JP4694841B2 (ja) | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
US7252675B2 (en) | 2002-09-30 | 2007-08-07 | Advanced Cardiovascular, Inc. | Embolic filtering devices |
UA80991C2 (en) * | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20040088000A1 (en) | 2002-10-31 | 2004-05-06 | Muller Paul F. | Single-wire expandable cages for embolic filtering devices |
DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
IN192749B (pt) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
DE10261067A1 (de) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
DE10302452B4 (de) * | 2003-01-23 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
US7976853B2 (en) * | 2003-01-29 | 2011-07-12 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US7572910B2 (en) * | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
US8591540B2 (en) | 2003-02-27 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Embolic filtering devices |
WO2004108067A2 (en) * | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
RU2005134659A (ru) * | 2003-04-09 | 2007-05-27 | Джапан Тобакко Инк. (Jp) | Гетероароматическое пентациклическое соединение и его применение в медицине |
US7820158B2 (en) * | 2003-04-10 | 2010-10-26 | Surmodics, Inc. | Ligand-coupled initiator polymers and methods of use |
EP1618893A4 (en) * | 2003-04-28 | 2009-08-12 | Sankyo Co | MEANS FOR INCREASING SUGAR CAPACITY |
CA2524134C (en) * | 2003-04-28 | 2017-07-04 | Sankyo Company Limited | Adiponectin production enhancer |
JP2007502847A (ja) * | 2003-05-13 | 2007-02-15 | シントン・ベスローテン・フェンノートシャップ | チアゾリジンジオン誘導体およびその化合物を製造する方法 |
US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
EP1638554A1 (en) * | 2003-06-27 | 2006-03-29 | Dr. Reddy's Research Foundation | Compositions comprising balaglitazone and further antidiabetic compounds |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
EP1651251A4 (en) * | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
MXPA06004698A (es) * | 2003-10-27 | 2006-07-05 | Innodia Inc | Metodos y composiciones para utilizarse en el tratamiento de la diabetes. |
BRPI0414979A (pt) * | 2003-10-31 | 2006-11-21 | Takeda Pharmaceutical | preparação sólida |
US7892251B1 (en) | 2003-11-12 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Component for delivering and locking a medical device to a guide wire |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
EP1732513A2 (en) * | 2003-12-31 | 2006-12-20 | Alpharma, Inc. | Rosiglitazone formulations |
US7360069B2 (en) * | 2004-01-13 | 2008-04-15 | Hewlett-Packard Development Company, L.P. | Systems and methods for executing across at least one memory barrier employing speculative fills |
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
WO2005074909A1 (ja) * | 2004-02-09 | 2005-08-18 | Aska Pharmaceutical Co., Ltd. | 併用医薬 |
EP1716144A2 (en) * | 2004-02-20 | 2006-11-02 | Synthon B.V. | Processes for making pioglitazone and compounds of the processes |
JP2007526309A (ja) * | 2004-03-02 | 2007-09-13 | アベール ファーマシューティカルズ インコーポレイテッド | 生物活性剤の混合製剤またはキット |
US7678129B1 (en) | 2004-03-19 | 2010-03-16 | Advanced Cardiovascular Systems, Inc. | Locking component for an embolic filter assembly |
US7161756B2 (en) * | 2004-05-10 | 2007-01-09 | Tandberg Data Storage Asa | Method and system for communication between a tape drive and an external device |
CN1327840C (zh) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | 一种药物组合物及其在制备用于治疗糖尿病中的应用 |
EP1773376A4 (en) * | 2004-08-03 | 2009-07-01 | Emisphere Tech Inc | ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION |
CN101432004A (zh) * | 2004-09-14 | 2009-05-13 | 伊利舍医药品公司 | 用于控制的碳水化合物消化的联合治疗 |
MXPA04009236A (es) * | 2004-09-23 | 2006-03-27 | Jorge Luis Rosado Loria | Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. |
JP2008019169A (ja) * | 2004-10-25 | 2008-01-31 | Osaka Univ | 新規ppar調節剤およびそのスクリーニング方法 |
US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US9259305B2 (en) | 2005-03-31 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Guide wire locking mechanism for rapid exchange and other catheter systems |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
WO2007007982A2 (en) * | 2005-07-07 | 2007-01-18 | Postech Foundation | Glucose uptake modulator and method for treating diabetes or diabetic complications |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
EP1906966A2 (en) * | 2005-07-22 | 2008-04-09 | The Procter and Gamble Company | Compositions for reducing the incidence of drug induced arrhythmia |
MXPA05013220A (es) * | 2005-12-06 | 2007-06-05 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. |
PE20110019A1 (es) | 2005-12-22 | 2011-01-27 | Takeda Pharmaceutical | Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina |
FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
ES2397944T3 (es) | 2006-03-16 | 2013-03-12 | Metabolic Solutions Development Company Llc | Análogos de tiazolidindiona |
CN101410105A (zh) * | 2006-03-31 | 2009-04-15 | 维尔斯达医疗公司 | 代谢紊乱的组合治疗 |
AU2007235737B2 (en) * | 2006-04-11 | 2011-12-08 | Sorbwater Technology As | Method for removal of materials from a liquid stream |
US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
CA2787343C (en) | 2006-06-26 | 2016-08-02 | Amgen Inc. | Compositions comprising modified lcat and uses thereof |
US7752724B2 (en) * | 2006-06-27 | 2010-07-13 | Lumino, Inc. | Method of cutting blinds |
WO2008026668A1 (fr) * | 2006-08-31 | 2008-03-06 | Daiichi Sankyo Company, Limited | Composition médicale contenant un agent d'amélioration de la résistance à l'insuline |
US20080182880A1 (en) * | 2006-09-28 | 2008-07-31 | Mailatur Sivaraman Mohan | Pioglitazone composition |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
WO2008091624A2 (en) * | 2007-01-22 | 2008-07-31 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
JP5301465B2 (ja) | 2007-01-25 | 2013-09-25 | バーバ・ファーマシューティカルズ・リミテッド | インスリン抵抗性改善薬および治療方法 |
KR101486091B1 (ko) * | 2007-02-01 | 2015-01-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 알로그립틴 및 피오글리타존을 포함하는 고형 제제 |
WO2008124122A1 (en) * | 2007-04-09 | 2008-10-16 | Scidose, Llc | Combinations of statins and anti-obesity agent and glitazones |
US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
KR101622403B1 (ko) | 2007-04-11 | 2016-05-31 | 오메로스 코포레이션 | 중독의 예방 및 치료용 조성물 및 방법 |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7867273B2 (en) | 2007-06-27 | 2011-01-11 | Abbott Laboratories | Endoprostheses for peripheral arteries and other body vessels |
US8168416B2 (en) | 2007-07-26 | 2012-05-01 | Amgen Inc. | Modified lecithin-cholesterol acyltransferase enzymes |
JP5371988B2 (ja) * | 2007-09-14 | 2013-12-18 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 高血圧を処置するためのチアゾリジンジオン類似体 |
JPWO2009038107A1 (ja) * | 2007-09-21 | 2011-01-06 | キッセイ薬品工業株式会社 | 2型糖尿病治療用の組合せ医薬 |
US20100311092A1 (en) * | 2007-11-30 | 2010-12-09 | Kurland Irwin J | Metabolic fuel switching biomarker |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
EP2190417A2 (en) * | 2008-03-26 | 2010-06-02 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
NZ619895A (en) | 2008-08-12 | 2015-12-24 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
MX2011009384A (es) | 2009-03-11 | 2011-10-11 | Omeros Corp | Composiciones y metodos para profilaxis y tratamiento de adicciones. |
US20110038848A1 (en) * | 2009-08-12 | 2011-02-17 | Melaleuca, Inc. | Dietary supplement compositions for cardiovascular health |
CA2780683A1 (en) | 2009-11-13 | 2011-05-19 | Toray Industries, Inc. | Therapeutic or prophylactic combination of a prostaglandin i2 and a thiazolidine for diabetes |
AU2010326268B2 (en) * | 2009-12-04 | 2016-11-03 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
MX2012006730A (es) * | 2009-12-15 | 2012-07-30 | Metabolic Solutions Dev Co Llc | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. |
KR102029611B1 (ko) * | 2009-12-15 | 2019-10-07 | 씨리우스 테라퓨틱스, 엘엘씨 | 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온염 |
WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
MX2012011631A (es) * | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
RU2526153C2 (ru) * | 2010-07-15 | 2014-08-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
WO2012028934A1 (en) | 2010-09-01 | 2012-03-08 | Lupin Limited | Pharmaceutical composition comprising metformin and pioglitazone |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
EA201691399A1 (ru) | 2011-01-10 | 2016-10-31 | Зинфандел Фармасьютикалз, Инк. | Способы и готовые лекарственные формы для лечения болезни альцгеймера |
US9566269B2 (en) * | 2011-01-20 | 2017-02-14 | Bionevia Pharmaceuticals Inc. | Modified release compositions of epalrestat or a derivative thereof and methods for using the same |
WO2013034174A1 (en) | 2011-09-06 | 2013-03-14 | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. | Solid preparations of pioglitazone and glimepiride |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
CA2858572C (en) | 2011-12-08 | 2023-01-17 | Amgen Inc. | Human lcat antigen binding proteins and their use in therapy |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
US20160235807A1 (en) | 2013-10-09 | 2016-08-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
RU2572706C1 (ru) * | 2014-06-30 | 2016-01-20 | Олег Ильич Эпштейн | Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция |
SG11201706347SA (en) | 2015-02-06 | 2017-09-28 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
US20190350907A1 (en) | 2017-01-16 | 2019-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
CN112955964B (zh) | 2018-06-14 | 2023-10-27 | 阿斯利康(英国)有限公司 | 用二甲双胍药物组合物降低血糖的方法 |
BR112021024109A2 (pt) | 2019-05-30 | 2022-03-22 | Intercept Pharmaceuticals Inc | Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática |
CN112869173A (zh) * | 2021-01-18 | 2021-06-01 | 广州富诺营养科技有限公司 | 一种复合维生素矿物质制剂及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5728073A (en) * | 1980-07-29 | 1982-02-15 | Takeda Chem Ind Ltd | Inhibitor for aldose reducing enzyme |
US4863922A (en) * | 1984-12-12 | 1989-09-05 | Merck & Co., Inc. | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
CA1310269C (en) | 1987-03-20 | 1992-11-17 | Billie M. York, Jr. | Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus |
DE3729209A1 (de) * | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
EP0842925A1 (en) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US4895862A (en) | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) * | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
JPH0466579A (ja) * | 1990-07-04 | 1992-03-02 | Yamanouchi Pharmaceut Co Ltd | チアゾリジン誘導体 |
JPH0469383A (ja) * | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
US5260275A (en) * | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
JP2686861B2 (ja) * | 1991-03-30 | 1997-12-08 | キッセイ薬品工業株式会社 | 新規なベンジリデンコハク酸誘導体 |
US5900435A (en) * | 1991-08-26 | 1999-05-04 | Pharmacia & Upjohn Company | Composition, food product and uses of 3-guanidinopropionic acid |
JPH05202042A (ja) * | 1992-01-24 | 1993-08-10 | Sankyo Co Ltd | 糖尿病性合併症治療剤 |
JPH07316144A (ja) * | 1994-03-29 | 1995-12-05 | Sankyo Co Ltd | ジフェニルメチルピペラジン誘導体 |
TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
US5674900A (en) * | 1995-06-06 | 1997-10-07 | Shaman Pharmaceuticals, Inc. | Terpenoid-type quinones for treatment of diabetes |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CA2180296C (en) * | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
GB9715298D0 (en) * | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US6001049A (en) * | 1998-02-12 | 1999-12-14 | Frey; Mark P. | Light weight exercise apparatus |
-
1996
- 1996-06-12 TW TW090105054A patent/TWI238064B/zh not_active IP Right Cessation
- 1996-06-12 TW TW085107042A patent/TW438587B/zh not_active IP Right Cessation
- 1996-06-18 SK SK1449-2001A patent/SK287287B6/sk not_active IP Right Cessation
- 1996-06-18 SK SK794-96A patent/SK287351B6/sk not_active IP Right Cessation
- 1996-06-18 JP JP15672596A patent/JP3148973B2/ja not_active Expired - Lifetime
- 1996-06-19 AR ARP960103195A patent/AR005641A1/es not_active Application Discontinuation
- 1996-06-19 RU RU96111958/63A patent/RU2323004C2/ru active
- 1996-06-19 CZ CZ19961811A patent/CZ291624B6/cs not_active IP Right Cessation
- 1996-06-19 MX MX9602399A patent/MX9602399A/es active IP Right Grant
- 1996-06-19 CN CNB021491313A patent/CN1289082C/zh not_active Expired - Fee Related
- 1996-06-19 RU RU96111958/14K patent/RU2198682C2/ru active IP Right Maintenance
- 1996-06-19 NO NO19962606A patent/NO313226B1/no not_active IP Right Cessation
- 1996-06-19 CN CNA021491321A patent/CN1530106A/zh active Pending
- 1996-06-19 CN CNB961110635A patent/CN1212117C/zh not_active Expired - Lifetime
- 1996-06-19 RU RU2002104459/14K patent/RU2223760C2/ru active IP Right Maintenance
- 1996-06-19 US US08/667,979 patent/US5952356A/en not_active Expired - Lifetime
- 1996-06-19 RU RU2002104459/63A patent/RU2327455C2/ru active
- 1996-06-19 ZA ZA9605190A patent/ZA965190B/xx unknown
- 1996-06-20 DE DE200912000064 patent/DE122009000064I1/de active Pending
- 1996-06-20 CA CA002179584A patent/CA2179584C/en not_active Expired - Lifetime
- 1996-06-20 EP EP10012501A patent/EP2289556A3/en not_active Withdrawn
- 1996-06-20 EP EP98200252A patent/EP0861666B1/en not_active Revoked
- 1996-06-20 EP EP10012500A patent/EP2292268A1/en not_active Withdrawn
- 1996-06-20 EP EP06022352A patent/EP1764110A1/en not_active Withdrawn
- 1996-06-20 DK DK98200252T patent/DK0861666T3/da active
- 1996-06-20 MY MYPI96002486A patent/MY127530A/en unknown
- 1996-06-20 PT PT98200252T patent/PT861666E/pt unknown
- 1996-06-20 CA CA2533845A patent/CA2533845C/en not_active Expired - Fee Related
- 1996-06-20 AT AT01203170T patent/ATE438397T1/de active
- 1996-06-20 EP EP01203170.4A patent/EP1174135B2/en not_active Expired - Lifetime
- 1996-06-20 KR KR1019960022615A patent/KR970000233A/ko not_active Application Discontinuation
- 1996-06-20 ES ES01203170.4T patent/ES2327383T5/es not_active Expired - Lifetime
- 1996-06-20 AT AT98200252T patent/ATE256463T1/de active
- 1996-06-20 DE DE69631157T patent/DE69631157T2/de not_active Expired - Lifetime
- 1996-06-20 DK DK01203170T patent/DK1174135T3/da active
- 1996-06-20 ES ES98200252T patent/ES2212208T3/es not_active Expired - Lifetime
- 1996-06-20 CA CA002531834A patent/CA2531834C/en not_active Expired - Lifetime
- 1996-06-20 PT PT01203170T patent/PT1174135E/pt unknown
- 1996-06-20 DE DE69637988T patent/DE69637988D1/de not_active Expired - Lifetime
- 1996-06-20 EP EP96304570A patent/EP0749751A3/en not_active Ceased
- 1996-06-20 HU HU9601698A patent/HUP9601698A3/hu not_active Application Discontinuation
-
1997
- 1997-12-26 JP JP36075697A patent/JP3973280B2/ja not_active Expired - Lifetime
-
1998
- 1998-04-09 US US09/057,465 patent/US5965584A/en not_active Expired - Lifetime
- 1998-10-22 HK HK98111476A patent/HK1010484A1/xx not_active IP Right Cessation
-
1999
- 1999-03-30 US US09/280,710 patent/US6150383A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,469 patent/US6133293A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,495 patent/US6172090B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,492 patent/US6166043A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,496 patent/US6121295A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,497 patent/US6156773A/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,494 patent/US6172089B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,468 patent/US6169099B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,470 patent/US6166042A/en not_active Expired - Lifetime
- 1999-04-30 US US09/302,508 patent/US6214848B1/en not_active Expired - Lifetime
- 1999-04-30 US US09/303,493 patent/US6150384A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,097 patent/US6225326B1/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,099 patent/US6133295A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,098 patent/US6080765A/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,095 patent/US6174904B1/en not_active Expired - Lifetime
- 1999-05-27 US US09/321,096 patent/US6121294A/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,504 patent/US6169100B1/en not_active Expired - Lifetime
- 1999-08-31 US US09/386,457 patent/US6103742A/en not_active Expired - Lifetime
- 1999-12-03 US US09/453,521 patent/US6329404B1/en not_active Expired - Lifetime
-
2000
- 2000-06-29 US US09/605,704 patent/US6303640B1/en not_active Expired - Lifetime
- 2000-06-29 US US09/606,176 patent/US6211205B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,994 patent/US6218409B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,993 patent/US6232330B1/en not_active Expired - Lifetime
- 2000-07-06 US US09/610,992 patent/US6288090B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,636 patent/US6239153B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,634 patent/US6323225B1/en not_active Expired - Lifetime
- 2000-07-18 US US09/618,635 patent/US6251924B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,640 patent/US6211206B1/en not_active Expired - Lifetime
- 2000-07-19 US US09/619,641 patent/US6211207B1/en not_active Expired - Lifetime
- 2000-09-01 NO NO20004345A patent/NO314065B1/no not_active IP Right Cessation
- 2000-11-28 US US09/722,597 patent/US6271243B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,291 patent/US6277869B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/722,330 patent/US6274605B1/en not_active Expired - Lifetime
-
2001
- 2001-07-19 US US09/907,768 patent/US20020002186A1/en not_active Abandoned
- 2001-10-11 US US09/973,689 patent/US6384062B1/en not_active Expired - Lifetime
-
2002
- 2002-02-21 HK HK02101272.5A patent/HK1041203B/zh not_active IP Right Cessation
- 2002-02-28 US US10/084,479 patent/US20020123512A1/en not_active Abandoned
- 2002-03-08 NO NONO/SPC/2A patent/NO317341B1/no not_active IP Right Cessation
- 2002-03-13 US US10/095,453 patent/US6599923B2/en not_active Expired - Lifetime
- 2002-07-15 CZ CZ20022453A patent/CZ292093B6/cs not_active IP Right Cessation
-
2003
- 2003-06-17 US US10/462,793 patent/US6911459B2/en not_active Expired - Fee Related
- 2003-10-20 RU RU2003130978/14A patent/RU2286148C2/ru not_active IP Right Cessation
-
2004
- 2004-02-19 CY CY0400010A patent/CY2424B1/xx unknown
- 2004-07-26 US US10/898,316 patent/US20040266830A1/en not_active Abandoned
- 2004-09-10 US US10/937,494 patent/US7144900B2/en not_active Expired - Fee Related
- 2004-10-07 KR KR1020040079966A patent/KR20070081135A/ko not_active Application Discontinuation
-
2006
- 2006-09-20 US US11/523,771 patent/US7538125B2/en not_active Expired - Fee Related
- 2006-12-20 LU LU91298C patent/LU91298I2/fr unknown
-
2007
- 2007-01-04 NO NO2007001C patent/NO2007001I2/no unknown
- 2007-01-08 DE DE200712000002 patent/DE122007000002I1/de active Granted
- 2007-01-08 CY CY200700001C patent/CY2007001I1/el unknown
- 2007-01-25 NL NL300258C patent/NL300258I2/nl unknown
- 2007-04-25 JP JP2007115861A patent/JP4809806B2/ja not_active Expired - Lifetime
- 2007-05-28 AR ARP070102280A patent/AR061195A2/es not_active Application Discontinuation
- 2007-06-04 NO NO2007007C patent/NO2007007I2/no unknown
- 2007-12-20 KR KR1020070134272A patent/KR20080005162A/ko not_active Application Discontinuation
-
2008
- 2008-02-20 AR ARP080100677A patent/AR065389A2/es not_active Application Discontinuation
-
2009
- 2009-03-20 US US12/382,691 patent/US7842706B2/en not_active Expired - Fee Related
- 2009-09-09 LU LU91606C patent/LU91606I2/fr unknown
- 2009-10-20 CY CY0900011A patent/CY2608B2/xx unknown
- 2009-10-23 FR FR09C0055C patent/FR09C0055I2/fr active Active
- 2009-12-01 CY CY2009018C patent/CY2009018I1/el unknown
-
2010
- 2010-01-15 NL NL300432C patent/NL300432I2/en unknown
- 2010-10-19 US US12/923,975 patent/US20110034518A1/en not_active Abandoned
-
2011
- 2011-01-06 AR ARP110100033 patent/AR091289A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK287351B6 (sk) | Farmaceutická kompozícia obsahujúca pioglitazón s glibenclamidom alebo s glimepiridom | |
US5780450A (en) | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage | |
US20060173011A1 (en) | Treatment of inflammatory disorders with praziquantel | |
US20060030572A1 (en) | Method of improved diuresis in individuals with impaired renal function | |
JP2010043101A (ja) | 組合せ | |
CN101668530A (zh) | 激活irs-1和akt的方法 | |
AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
US20220409598A1 (en) | Method of controlling blood sugar level and treatment of diabetes and related conditions | |
US8106081B2 (en) | Combination of organic compounds useful for treating diabetes | |
AU2001262741B2 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
JPH07118148A (ja) | 肝癌予防剤 | |
JP2005239712A (ja) | 神経突起伸展剤 | |
KR20090024248A (ko) | Cxcr2의 선택적 길항제 또는 cxcr1과 cxcr2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법 | |
DE3904795C2 (de) | Pharmazeutisches Präparat und dessen Verwendung | |
US20060173028A1 (en) | Therapeutic and/or preventive agent for chronic skin disease | |
JP3064027B2 (ja) | 血管新生阻害剤 | |
US20230330077A1 (en) | Use of sphingosine-1-phosphate receptor agonist | |
Perucca et al. | Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly | |
EP1932529A1 (en) | Method of improved diuresis in individuals with impaired renal function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of an spc |
Free format text: PRODUCT NAME: PIOGLITAZON A GLIMEPIRID; REGISTRATION NO/DATE: EU/1/06/366/001 - EU/1/06/366/022 20070108 Spc suppl protection certif: 5010-2010 Filing date: 20100615 |
|
SPCG | Grant of an spc |
Free format text: PRODUCT NAME: PIOGLITAZON A GLIMEPIRID; REGISTRATION NO/DATE: EU/1/06/366/001 - EU/1/06/366/022 20070108 Spc suppl protection certif: 95 5010-2010 Filing date: 20100615 Expiry date: 20160619 Extension date: 20210619 |
|
MK4A | Patent expired |
Expiry date: 20160618 |
|
SPCE | Expiry of an spc |
Spc suppl protection certif: 95 5010-2010 Effective date: 20210619 |